# Illimis Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/illimis-therapeutics

- Industry: Biotechnology
- Headquarters: Seoul, South Korea
- Website: www.illimistx.com
- Total disclosed funding: $59M
- Latest round: Series B (Jul 2, 2025)
- Investors on record: 25

## About

Illimis Therapeutics focuses on developing innovative therapies for central nervous system disorders, emphasizing improving treatment options for Alzheimer's disease through its unique therapeutic platform.Founded in 2021 in Seoul, South Korea, Illimis Therapeutics specializes in treatments for central nervous system disorders. Co-founders Chan Kim and Sanghoon Park lead the company, which has raised a total of KRW 20 billion through its Series A funding round, with its most recent deal occurring on April 5, 2023. The company has made a total of 3 deals and is not affiliated with a parent company or subsidiary.Illimis Therapeutics specializes in the development of innovative treatments for central nervous system (CNS) disorders, particularly focusing on Alzheimer's disease through its flagship product, GAIA-Aß. This approach aims to enhance the safety profile of existing Alzheimer's treatments and improve patient outcomes. Utilizing TAM receptors instead of Fc receptors, Illimis aims to reduce neuroinflammation and foster a healthier immune environment in the brain. The GAIA platform is currently in the preclinical stages and targets both Alzheimer's patients and their families seeking better quality of life. The company distributes its products in various international markets, addressing significant unmet needs in CNS disease management.In 2023, Illimis Therapeutics reported no revenue. The company successfully completed a Series A funding round, raising KRW 20 billion (approximately USD 15 mn), which will support its research and development, particularly for its lead product, ILM01. Revenue streams are expected from partnerships with pharmaceutical firms and licensing agreements tied to clinical development milestones and future royalties.Illimis Therapeutics plans to utilize the KRW 20 billion raised in its Series A funding to advance its research initiatives, particularly for its flagship product, GAIA-Aß. The company aims to expand its market reach, with specific targets for international markets that have high unmet needs in CNS treatment, with further details on the regions targeted to be outlined as the product progresses. As Illimis continues to develop its pipeline, they will also focus on establishing a B2B model that directly connects with healthcare providers and institutions, facilitating broader access to its innovative therapies.

## Funding rounds

- Series B, Jul 2, 2025, $43M — Korea Development Bank, AJU IB Investment, LB Investment, Shinhan Venture Investment, WOORI Venture Partners, Industrial Bank of Korea, DSC Investment, IMM Investment, Company K Partners, QUAD Investment Management, T.S. Investment, COMES Investment, Maple Investment Partners, Schmidt, DAYLI Partners, A Ventures, S&S Investment, GS Ventures, Hana Ventures
- Series A, Apr 5, 2023, $15M — Korea Development Bank, AJU IB Investment, WOORI Venture Partners, WONIK Investment Partners, Company K Partners, NH Investment & Securities, LSK Investment, QUAD Ventures, STIC Ventures, DAYLI Partners, GS Ventures
- Seed, Sep 30, 2021, $1M — AJU IB Investment, Korea Tech Incubator for Startup

## Investors

- AJU IB Investment (https://capitalatlas.ai/funds/aju-ib-investment) — Seed, Series A, Series B
- Korea Tech Incubator for Startup — Seed
- Korea Development Bank (https://capitalatlas.ai/funds/korea-development-bank) — Series A, Series B
- WOORI Venture Partners (https://capitalatlas.ai/funds/woori-venture-partners) — Series A, Series B
- WONIK Investment Partners (https://capitalatlas.ai/funds/wonik-investment-partners) — Series A
- Company K Partners (https://capitalatlas.ai/funds/company-k-partners) — Series A, Series B
- NH Investment & Securities (https://capitalatlas.ai/funds/nh-investment-securities) — Series A
- LSK Investment (https://capitalatlas.ai/funds/lsk-investment) — Series A
- QUAD Ventures (https://capitalatlas.ai/funds/quad-ventures) — Series A
- STIC Ventures (https://capitalatlas.ai/funds/stic-ventures) — Series A
- DAYLI Partners (https://capitalatlas.ai/funds/dayli-partners) — Series A, Series B
- GS Ventures (https://capitalatlas.ai/funds/gs-ventures) — Series A, Series B
- LB Investment (https://capitalatlas.ai/funds/lb-investment) — Series B
- Shinhan Venture Investment (https://capitalatlas.ai/funds/shinhan-venture-investment) — Series B
- Industrial Bank of Korea — Series B
- DSC Investment (https://capitalatlas.ai/funds/dsc-investment) — Series B
- IMM Investment (https://capitalatlas.ai/funds/imm-investment) — Series B
- QUAD Investment Management (https://capitalatlas.ai/funds/quad-investment-management) — Series B
- T.S. Investment (https://capitalatlas.ai/funds/t-s-investment) — Series B
- COMES Investment (https://capitalatlas.ai/funds/comes-investment) — Series B
- Maple Investment Partners (https://capitalatlas.ai/funds/maple-investment-partners) — Series B
- Schmidt (https://capitalatlas.ai/funds/schmidt) — Series B
- A Ventures — Series B
- S&S Investment (https://capitalatlas.ai/funds/s-s-investment) — Series B
- Hana Ventures — Series B